Blog

Immunotherapy for Lung Cancer: Are Combination Regimens a Path Forward? – Cancer Therapy Advisor


Cancer Therapy Advisor

Immunotherapy for Lung Cancer: Are Combination Regimens a Path Forward?
Cancer Therapy Advisor
The results have been “eagerly awaited because both IL-15 and PD-1 or PD-L1 blockers are ranked in the top three classes of immunotherapy drugs that could potentially cure cancer,” Dr Rolfo and Dr Smits wrote. “IL-15 triggers the activation of both

2018-05-14 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.